Clinical importance of stem cells in T2D treatment: A systematic review
Paper Details
Clinical importance of stem cells in T2D treatment: A systematic review
Abstract
Advanced pharmacological treatments have not been able to effectively manage the course of type 2 diabetes mellitus [T2DM] as a result of these challenges to investigate the possible intervention of regenerative medicine such as stem-cell therapies to restore metabolic functions and improve complications of diabetes. The systematic review was done in accordance with PRISMA 2020, PubMed/MEDLINE [2016-2026] were searched on the topic of stem cell therapies in T2DM. Eight studies [RCTs, Phase I-IV trials, observational and case studies] were counted, and they were based on bone marrow-derived MSCs, adipose-derived stromal cells, and umbilical cord-derived MSCs. MSC based therapy has shown high therapeutic promise in T2DM with a consistent improvement in the HbA1C, glycemic control and 8-cell performance, especially using umbilical cord MSCs and bone marrow MSCs. Metabolic results are further improved as a consequence of combination [e.g., in hyperbaric oxygen]. The long-term outcomes such as long-term glycemic control and 8 years of 15 8cell functioning have been reported. The complications that have been reported to have improved notably include wound healing, limb perfusion, and slowed down kidney disease progression. These processes are mediated by β-cell regeneration in patients with long-term diabetes, which demonstrates the benefit of early intervention. Regenerative therapies through stem cells offer an option to treat T2DM. The approaches have the potential to improve glycemic control and result in improvements in complications associated with diabetes.
Carstens MH, Quintana FJ, Calderwood ST, Sevilla JP, Ríos AB, Rivera CM. 2021. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Translational Medicine 10, 1138–1147.
Chen Y, Ma Y, Li N, Wang H, Chen B, Liang Z. 2018. Efficacy and long-term longitudinal follow-up of bone marrow mesenchymal cell transplantation therapy in a diabetic patient with recurrent lower limb bullosis diabeticorum. Stem Cell Research and Therapy 9, 99.
Estrada EJ, Decima JL, Bortman G, Roberti J, Romero EB, Samaja G. 2019. Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial. Cell Transplantation 28, 1632–1640.
Gao S, Zhang Y, Liang K, Bi R, Du Y. 2022. Mesenchymal stem cells: A novel therapy for type 2 diabetes. Stem Cells International 2022, 8637493.
Habiba UE, Khan N, Greene DL, Shamim S, Umer A. 2024. The therapeutic effect of mesenchymal stem cells in diabetic kidney disease. Journal of Molecular Medicine 102, 537–570. DOI: 10.1007/s00109-024-02432-w.
Huang J, Deng Q, Tsang LL, Chang G, Guo J, Ruan YC, Wang CC, Li G, Chan HF, Zhang X, Jiang X. 2025. Mesenchymal stem cells from perinatal tissues promote diabetic wound healing via PI3K/AKT activation. Stem Cell Research and Therapy 16, 59. DOI: 10.1186/s13287-025-04141-8.
Jafar H, Almousa R, Alhawari H, Shahin D, Al Soudi M, Abusharieh E. 2025. Umbilical cord mesenchymal stromal cell derivatives in treating diabetic foot ulcers: A phase I/II trial. Stem Cell Research and Therapy 16, 657.
Jeyaraman M, Nagarajan S, Maffulli N, et al. 2023. Stem cell therapy in critical limb ischemia. Cureus 15, e41772.
Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X. 2011. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: A pilot study. Frontiers in Medicine 5, 94–100.
Kiehl C, Simmenroth-Nayda A, Goerlich Y, Entwistle A, Schiekirka S, Ghadimi BM. 2014. Standardized and quality-assured video-recorded examination in undergraduate education: Informed consent prior to surgery. Journal of Surgical Research 191, 64–73.
Koishybayeva D, Amirashov A, Balmagambetova S, Mussin NM, Tamadon A. 2025. Mesenchymal stem cell therapy for diabetes: An umbrella review. Tissue and Cell 96, 103043.
Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y. 2014. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Research and Therapy 5, 57. DOI: 10.1186/scrt446.
Lu D, Jiang Y, Deng W, Zhang Y, Liang Z, Wu Q. 2019. Long-term outcomes of BMMSC compared with BMMNC for treatment of critical limb ischemia and foot ulcer in patients with diabetes. Cell Transplantation 28, 645–652.
Mateen MA, Alaagib N, Haider KH. 2024. High glucose microenvironment and human mesenchymal stem cell behavior. World Journal of Stem Cells 16(3), 237–244. DOI: 10.4252/wjsc.v16.i3.237.
Mathur A, Taurin S, Alshammary S. 2023. Safety and efficacy of mesenchymal stem cells in type 2 diabetes: A literature review. Diabetes, Metabolic Syndrome and Obesity 16, 769–777.
Nguyen LT, Hoang DM, Nguyen KT, Bui DM, Nguyen HT, Le HTA. 2021. Type 2 diabetes duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem cells. Stem Cells Translational Medicine 10, 1266–1278.
Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F. 2023. Safety and preliminary efficacy of mesenchymal stromal cell therapy in diabetic kidney disease: A randomized clinical trial. Journal of the American Society of Nephrology 34, 1733–1751.
Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ. 2011. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 54, 1127–1135.
Shi Y, Wang S, Zhang W, Zhu Y, Fan Z, Huang Y, et al. 2022. Bone marrow mesenchymal stem cells facilitate diabetic wound healing via restoration of epidermal autophagy. Stem Cell Research and Therapy 13, 314.
Soria-Juan B, Garcia-Arranz M, Llanos Jiménez L, Aparicio C, Gonzalez A, Mahillo Fernandez I. 2021. Efficacy and safety of intramuscular administration of allogeneic adipose tissue-derived mesenchymal stromal cells in diabetic patients with critical limb ischemia: Study protocol for a randomized controlled trial. Trials 22, 595. DOI: 10.1186/s13063-021-05430-2.
Velikova T, Dekova T, Miteva DG. 2024. Controversies regarding transplantation of mesenchymal stem cells. World Journal of Transplantation 14(2), 90554. DOI: 10.5500/wjt.v14.i2.90554.
Wu Z, Huang S, Li S, Cai J, Huang L, Wu W, et al. 2024. Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in type 2 diabetes mellitus: A randomized controlled study with 8-year follow-up. Stem Cell Research and Therapy 15, 339.
Xu J, Zgheib C, Hodges MM, Caskey RC, Hu J, Liechty KW. 2017. Mesenchymal stem cells correct impaired diabetic wound healing by decreasing ECM proteolysis. Physiological Genomics 49, 541–548.
Zang L, Li Y, Hao H, Liu J, Cheng Y, Li B, et al. 2022. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in adults with type 2 diabetes: A randomized placebo-controlled phase II trial. Stem Cell Research and Therapy 13, 180.
Zang L, Li Y, Hao H, Liu J, Zhang Q, Gao F. 2023. Efficacy of umbilical cord-derived mesenchymal stem cells in type 2 diabetes assessed by continuous glucose monitoring. Stem Cells Translational Medicine 12, 775–782.
Zhang J, Suo M, Wang J, Liu X, Huang H, Wang K, Liu X, Sun T, Li Z, Liu J. 2024. Standardisation is the key to the sustained, rapid and healthy development of stem cell-based therapy. Clinical and Translational Medicine 14(4), e1646. DOI: 10.1002/ctm2.1646.
Zhao Y, Jiang Z, Delgado E, Li H, Zhou H, Hu W. 2017. Platelet-derived mitochondria display embryonic stem cell markers and improve pancreatic islet β-cell function in humans. Stem Cells Translational Medicine 6, 1684–1697.
Mirza Masroor Ali Beg*, Nilam Bhasker, Tridiv Katiyar, Amar Chandra Sharma, 2026. Clinical importance of stem cells in T2D treatment: A systematic review. Int. J. Biosci., 29(1), 130-137.
Copyright © 2026 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.